Dazadrol
Appearance
![]() | |
Clinical data | |
---|---|
Other names | Sch 12650 |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.158 |
Chemical and physical data | |
Formula | C15H14ClN3O |
Molar mass | 287.75 g·mol−1 |
3D model (JSmol) | |
| |
|
Dazadrol is a synthetic antidepressant developed by Schering Corp in the late 1960s. It acts primarily as a noradrenaline reuptake inhibitor, increasing concentrations of noradrenaline in the synaptic cleft, which is believed to underlie its antidepressant effects.[1][2][3]
Dazadrol is classified as a pyridinemethanol derivative and has been studied for its impact on neurological function and mood. In addition to its antidepressant activity, preclinical studies in rats have shown that it inhibits both basal and induced gastric acid secretion, indicating potential gastrointestinal effects.[1][3][4][2]
See also
[edit]References
[edit]- ^ a b "Dazadrol". Inxight Drugs. The National Center for Advancing Translational Sciences (NCATS).
- ^ a b Lippmann W (May 1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2-[p-chlorophenyl-2-(pyridyl)hydroxymethyl] imidazoline maleate (Sch-12650)". The Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x. PMID 4393004.
- ^ a b Schmitt H, Petillot N (1971). "[Pharmacological properties of a new potential antidepressant: ((p-chlorophenyl)-2-(pyridyl)-hydroxymethyl) imidazoline (SCH 12.650)]". Therapie (in French). 26 (4): 805–821. PMID 5119131.
- ^ Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 978-0-412-46630-4.